Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms + [6] |
Target |
Mechanism HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | US | - | |
Solid tumor | Preclinical | US | 18 Apr 2023 | |
Solid tumor | Preclinical | US | 18 Apr 2023 |